Mannkind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.
Recent Communications
2007 Annual Report.
In 2007, we made substantial progress toward our goal of bringing Technosphere Insulin to diabetes patients.more
MannKind Corporation Response to Recent Market Events.
Mannkind is absolutely committed to the continued development of its lead development product, Technosphere Insulin.
more
MannKind Addresses Pfizer's Announcement Regarding Exubera
Our Technosphere Insulin clinical program is designed to provide data on safety and efficacy in a broad group of patients with diabetes.
Work on treatments with the potential for worldwide impact, and help create a better world inside: find a career at MannKind
| STOCK | PRICE | CHANGE | %CHANGE |
| MNKD | 2.79 |  -0.07 | -2.45% |
| Jul 3 2008 1:00PM | 20 min. delay | ||
